Adaptive Biotechnologies Corp (ADPT)vsMerck & Company Inc (MRK)
ADPT
Adaptive Biotechnologies Corp
$24.20
-0.12%
HEALTHCARE · Cap: $3.90B
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 21508% more annual revenue ($66.57B vs $308.08M). MRK leads profitability with a 4.8% profit margin vs -20.7%. MRK earns a higher WallStSmart Score of 36/100 (F).
ADPT
Avoid28
out of 100
Grade: F
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+51.0%
Fair Value
$31.91
Current Price
$24.20
$7.71 discount
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 21.5% year-over-year
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
0.0% earnings growth
Trading at 26.9x book value
ROE of -23.0% — below average capital efficiency
Negative free cash flow — burning cash
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ADPT
The strongest argument for ADPT centers on Revenue Growth. Revenue growth of 21.5% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : ADPT
The primary concerns for ADPT are EPS Growth, Price/Book, Return on Equity. Debt-to-equity of 2.87 is elevated, increasing financial risk.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
ADPT profiles as a growth stock while MRK is a value play — different risk/reward profiles.
ADPT carries more volatility with a beta of 2.10 — expect wider price swings.
ADPT is growing revenue faster at 21.5% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (36/100 vs 28/100). ADPT offers better value entry with a 51.0% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adaptive Biotechnologies Corp
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?